United States

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, currently in Phase II clinical trial for COVID-19 treatment. The company also develops other antiviral drugs for dengue, HCV, and other RNA viral infections. Atea has a license agreement with Merck & Co for the development and commercialization of ruzasvir for HCV treatment. The company was founded in 2012 and is based in Boston, Massachusetts.

Google

Gestor de producte

Científic de dades

Atea Pharmaceuticals

Atea Pharmaceuticals Feines Obertes

Estàs preparat per fer un salt en la teva carrera? Revisa aquests llocs oberts a Atea Pharmaceuticals.